Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6401
pubmed:dateCreated
1984-1-7
pubmed:abstractText
Oral progesterone 100, 200, or 300 mg daily was given for the first 10 days of each calendar month to postmenopausal women also receiving conjugated oestrogens 1.25 mg daily continuously. Endometrial biopsy specimens were taken on the sixth day of the third or subsequent cycle of combined treatment for histological, ultrastructural, and biochemical evaluation. Secretory histological changes were induced within the endometrium in a dose dependent manner, as were progesterone sensitive ultrastructural features such as nucleolar channel systems, giant mitochondria, and subnuclear accumulations of glycogen. Dose response relations were also observed for suppression of DNA synthesis and nuclear oestrogen receptor, and for induction of the activities of oestradiol and isocitric dehydrogenases. Progesterone administered by mouth clearly provokes an end organ response within the endometrium. Suboptimal effects were observed with the lower doses but progesterone 300 mg daily achieved responses approaching and within the physiological range. This dose may therefore be effective as an alternative to synthetic progestogens for therapeutic purposes.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-1196559, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-172466, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-193398, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-207983, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-427751, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-552525, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-5944275, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-6112292, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-6112410, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-6261039, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-6278933, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-6989989, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7009219, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7039319, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7062737, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7131447, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7193603, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7300331, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7312007, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7370683, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-7388443, http://linkedlifedata.com/resource/pubmed/commentcorrection/6315123-755956
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0267-0623
pubmed:author
pubmed:issnType
Print
pubmed:day
29
pubmed:volume
287
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1241-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't